Molnupiravir is effective in patients with haematological malignancies.
COVID-19
SAR-CoV-2
molnupiravir
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
revised:
03
12
2022
received:
05
10
2022
accepted:
05
01
2023
medline:
21
7
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Patients with hematologic malignancies are particularly vulnerable to severe infectious complications. SARS-CoV-2 infection is associated with a high risk of severe course and death in this patient population. In addition, immune deficits associated with both the blood cancer and the treatment used make vaccination against SARS-CoV-2 less effective than in immunocompetent individuals. Molnupiravir is one of the first oral antiviral drugs to demonstrate a significant benefit in reducing hospitalisation and death in COVID-19 in the general population. In this context, 175 haematology patients with diagnosed COVID-19, and treated with MOL between January and April 2022, came under our scrutiny with a view to defining their clinical characteristics and outcomes. The most common underlying conditions were lymphomas (45%), multiple myelomas (21%) and acute leukaemias or myelodysplastic syndrome (35%). Of all, 77% of the patients were vaccinated, and half of them received a booster. At 28 days after the breakthrough COVID-19 diagnosis, 35 (20%) subjects required hospital admission. Out of those patients, seven (4%) died during the follow-up due to the progression of COVID. Our results corroborate what has been established to date with regard to the positive clinical and safety outcomes of MOL in haematology patients with mild or moderate COVID-19.
Substances chimiques
molnupiravir
YA84KI1VEW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251-1256Informations de copyright
© 2023 UICC.
Références
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub. Blood Adv. 2020;4(23):5966-5975.
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745.
Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427-2438.
Lim SH, Campbell N, Johnson M, et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021;8(8):e542-e544.
Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021;11(7):1-8.
Zaleska J, Kwasnik P, Paziewska M, et al. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients. Int J Cancer. 2022;6:1322-1323.
Mader A-L, Tydykov L, Glück V, et al. Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. IScience. 2022;25(4):104076.
Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022;198:105252.
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1):100770.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-520.
El Chaer F, Auletta JJ, Chemaly RF. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. Blood. 2022;140(7):673-684.
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):1-15.
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 in vaccinated adult patients with haematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139(10):1588-1592.
Martínez JC, Sica RA, Stockerl-Goldstein K, Rubinstein SM. COVID-19 in patients with hematologic malignancies: outcomes and options for treatments. Acta Haematol. 2022;145(3):245-257.
Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-1484.
Vena A, Traman L, Bavastro M, et al. Early clinical experience with Molnupiravir for mild to moderate breakthrough COVID-19 among fully vaccinated patients at risk for disease progression. Vaccine. 2022;10(7):1141.
Flisiak R, Zarębska-Michaluk D, Rogalska M, et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 omicron variant dominance. Pharmacol Rep. 2022;74:1279-1285.
Puła B, Pruszczyk K, Pietrusza E, et al. Outcome of SARS-CoV-2-infected polish patients with chronic lymphocytic leukemia. Cancers. 2022;14(3):558.
Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia. 2020;34(9):2354-2363.
Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143.
Chatzikonstantinou T, Kapetanakis A, Scarfò L, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukaemia. 2021;35(12):3444-3454.